Skip to main content
. Author manuscript; available in PMC: 2019 Nov 12.
Published in final edited form as: Cancer Cell. 2018 Oct 25;34(5):792–806.e5. doi: 10.1016/j.ccell.2018.09.010

Figure 6. HER2 inhibitory drugs are effective in blocking HER2 TMD/JMD mutants.

Figure 6.

(A) Cartoon of HER2 depicting binding of trastuzumab and pertuzumab to ECD domain IV and domain II, respectively. (B) Effect of indicated anti-HER antibodies and the Fab portion of pertuzumab on survival of BaF3 cells expressing HER2 G660D mutant. (C-F) Effect of trastuzumab (C), pertuzumab (D), neratinib (E), and afatinib (F) on IL-3 independent survival of BaF3 cell expressing the indicated HER2 mutants. Data shown in (B-F) are mean ± SEM, where SEM is standard error of mean of four technical replicates and representative of experiment repeated three independent times. RLU = Relative luciferase units; EV = empty vector; WT = wild-type HER2. (G) Kaplan-Meier survival curves for cohorts of mice (n = 10) implanted with HER2 G660D expressing BaF3 cells that were either untreated or treated with anti-Ragweed (control) or trastuzumab. WT HER2 expressing BaF3 cells served as controls. See also Figures S4, S5 and Tables S3, S4.